Summary of Conference Call Records Company Overview - **Company**: 贝加洁 (Beijiajie) - **Industry**: Oral Care and Probiotics Key Financial Performance - **Revenue Growth**: 2025 H1 revenue increased by 10.22% to 717 million CNY, with net profit rising by 31.31% to 43.52 million CNY [2][3] - **Cash Flow**: Operating cash flow grew by 21.85% to 79.7 million CNY [2][3] - **Core Products**: Oral care products generated 485 million CNY, up 20.77%, while toothbrush sales declined by 4.81% due to reduced orders [2][4] Product Performance - **Toothpaste**: Significant growth in toothpaste revenue, contributing over 70 million CNY, a substantial increase from the previous year [2][6] - **OEM Business**: OEM revenue reached 608 million CNY, up 8.22%, driven by toothpaste sales despite declines in wet wipes and toothbrushes [2][9] - **Private Label**: Private label revenue was 55.21 million CNY, a 36% increase, but still incurred a loss of 10.42 million CNY [2][10] Market Performance - **Domestic Market**: Domestic revenue was 285 million CNY, up 29%, largely due to toothpaste sales [2][12] - **International Market**: International revenue was 378 million CNY, showing a slight decline of 0.1% [2][12] Customer Relationships - **Key Clients**: Strong partnerships with Procter & Gamble and Comfort Dental, with significant contributions to revenue [2][7] - **Client Structure Improvement**: Enhanced client structure with notable contributions from new clients [2][21] Future Development Focus - **Market Expansion**: Plans to deepen existing markets and explore new business areas, particularly in oral care and probiotics [2][8] - **Product Innovation**: Emphasis on technological innovation and strategic partnerships to diversify product offerings [2][8] Subsidiary Performance - **善恩康 (Shan'enkang)**: Achieved 49.76 million CNY in revenue, an 80% increase, turning a profit of 8.38 million CNY [2][13] Challenges and Strategies - **E-commerce Performance**: E-commerce channels showed mixed results, with significant losses from Douyin despite overall growth in online sales [2][11][10] - **Competitive Pricing**: The company is actively responding to market competition by adjusting pricing strategies and focusing on high-margin products [2][14][34] Conclusion - **Growth Outlook**: The company aims for double-digit growth in the coming years, leveraging its strengths in OEM and private label businesses while navigating market challenges [2][28]

Summary of the Conference Call for Beijiajie Company Overview - **Company**: Beijiajie - **Period**: First half of 2025 - **Revenue**: 6.63 billion CNY, a year-on-year increase of 10.2% [2][9] - **Net Profit**: 435.2 million CNY, a year-on-year increase of 31.31% [3] - **Gross Margin**: Increased by 1.21 percentage points to 25% [11] Key Points Revenue Growth - **Total Revenue Growth**: After merging with Shanenkang, total revenue growth reached 15.6% [2] - **Domestic vs. Overseas**: Domestic business revenue grew by 29%, while overseas business slightly decreased by 0.1% [2][9] Product Performance - **Oral Care Products**: Revenue of 4.85 billion CNY, a year-on-year increase of 21% [4] - **Toothbrushes**: Revenue decreased by 4.81% to 2.38 billion CNY [4] - **Dental Floss**: Revenue increased by 35% to 707.5 million CNY [4] - **Toothpaste**: Significant growth due to partnerships with major clients [4] - **Wet Wipes**: Revenue of 1.78 billion CNY, a year-on-year decrease of 10.8%, but gross margin improved to 23.48% [5] - **Shanenkang Probiotics**: Revenue of 48.98 million CNY, a significant year-on-year increase, achieving a net profit of 8.38 million CNY [6][13] Brand Performance - **Self-owned Brand Beijiajie**: Revenue of 55.21 million CNY, a year-on-year increase of 36%, but still incurred a loss of 10.42 million CNY [8] - **E-commerce Performance**: 45% of online sales from Douyin, which is the main source of losses [8] Operational Insights - **OEM Business**: Revenue of 6.08 billion CNY, a year-on-year increase of 8% [7] - **Production Capacity Utilization**: Toothbrush capacity utilization at 70%, with plans to increase toothpaste production lines [21] Market Dynamics - **Impact of Tariff Policies**: April tariff policies temporarily affected orders and shipping, but the situation has normalized [23] - **Regional Performance**: European region saw over 20% growth, while the U.S. market faced challenges due to decreased demand for medical wet wipes [22] Future Outlook - **Revenue Guidance**: Aiming for double-digit growth, with a bottom line of 10% for the year [26] - **Investment in R&D**: Shanenkang's R&D investment ratio is expected to be over 15%, focusing on next-generation probiotics [19] Additional Notes - **Challenges**: The company faced its first loss in history this year, but plans to improve operational performance and provide returns to investors [27] Conclusion Beijiajie demonstrated solid revenue growth in the first half of 2025, driven by strong domestic performance and strategic partnerships. However, challenges in the overseas market and specific product lines, such as wet wipes and toothbrushes, highlight areas for improvement. The company remains focused on maintaining growth and enhancing profitability through strategic investments and operational efficiencies.

Industry Trends - The per capita consumption of probiotics in China is significantly lower than in developed countries, with only $0.4 per person compared to $10.6 in Italy, $6.8 in the USA, and $6.3 in Japan, indicating substantial growth potential [1] - The focus on health and the rise of new consumption patterns are driving an increase in probiotic penetration, with a projected 7.4% year-on-year increase in per capita service consumption expenditure in 2024, reaching 13,016 yuan [1] - Domestic research on probiotics has increased over 60 times, with a tenfold increase in global patent technology share, leading to a structural shift from reliance on imports to local supply [1] Market Size and Growth - The market size for probiotic raw materials is expected to exceed 10 billion yuan, with a projected scale of 8.3 billion yuan in 2024, growing to 10.6 billion yuan by 2027 [2] - The demand for probiotics in infant formula is crucial due to the sensitivity of infants' digestive systems, with premium pricing for probiotic-added products [2] - The weight loss market presents a new opportunity for probiotics, as leading weight loss drug companies are experiencing high revenue growth [2] Company Developments - The company Keta has broken the market monopoly of foreign giants with its core strains, investing 36.3 million yuan in R&D in 2024, which is 12% of its revenue, marking a historical high [3] - New strains developed by Keta, such as ProSci-246, have shown significant health benefits, including weight loss and improved metabolic indicators [3] - Keta's new production capacity is expected to reach 950 tons, with a new facility in Inner Mongolia projected to be operational by 2025 [4] Strategic Initiatives - Keta's strategic partnership with Wuka Laboratory, which focuses on metabolic management and health, is expected to enhance its market position, with Wuka achieving over 600 million yuan in sales in the first half of 2025 [4] - The collaboration with Wuka is anticipated to provide Keta with a core channel for consumer-facing products, enhancing future growth prospects [4]

Core Viewpoint - The company received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting a detailed response about its financial performance and customer relationships [1][2]. Financial Performance - The company achieved a revenue of 1.299 billion RMB in 2024, representing a year-on-year growth of 21.78%. The overseas business contributed 784 million RMB, accounting for 60.35% of total revenue [2][3]. - The gross profit margin for overseas business was 25.44%, which is 4.81 percentage points higher than that of domestic business [2][3]. Customer Information - The company provided detailed information on major customers, including transaction amounts and accounts receivable balances for both domestic and overseas clients [3][4]. - The top overseas customer generated sales of 132.93 million RMB in 2024, while the top domestic customer generated sales of 66.34 million RMB [3][4]. Gross Margin Analysis - The difference in gross margins between overseas and domestic sales is attributed to the product mix and pricing strategies. The overseas sales model allows for higher pricing due to the demand for premium products [8][9]. - The gross margin for oral care products overseas is 7.83 percentage points higher than that of domestic sales, while for wet wipes, the difference is 11.4 percentage points [8][9]. Revenue Growth Drivers - The revenue growth is driven by increased customer demand, new product development, and the expansion of sales channels, including the acquisition of Shen'enkang, which contributed to the overall revenue increase [13][14]. - The main categories contributing to revenue growth include oral care products, wet wipes, and probiotics, with oral care products alone generating 843.15 million RMB in 2024, up 16.80% from the previous year [13][14]. Acquisition and Goodwill Impairment - The company acquired 52% of Shen'enkang, which resulted in a goodwill of 91.01 million RMB. However, Shen'enkang did not meet its performance commitments in 2024, leading to a goodwill impairment of 39.62 million RMB [14][15].